FDC rises on entering into definitive agreement with GlaxoSmithKline Pharmaceuticals

18 Oct 2019 Evaluate

FDC is currently trading at Rs. 161.75, up by 0.25 points or 0.15% from its previous closing of Rs. 161.50 on the BSE.

The scrip opened at Rs. 162.90 and has touched a high and low of Rs. 162.90 and Rs. 161.50 respectively.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 219.95 on 31-Oct-2019 and a 52 week low of Rs. 148.20 on 19-Feb-2019.

Last one week high and low of the scrip stood at Rs. 163.35 and Rs. 152.50 respectively. The current market cap of the company is Rs. 2765.49 crore.

The promoters holding in the company stood at 69.07%, while Institutions and Non-Institutions held 14.62% and 16.31% respectively.

FDC has entered into definitive documents (including a trademark assignment deed) on October 16, 2019 with GlaxoSmithKline Pharmaceuticals (GSK) for acquiring the registered Trademark ‘ENTEROPLUS’ from GSK. The Company would have acquired all the rights of this Trademark/Brand 'ENTEROPLUS'.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

414.65 0.80 (0.19%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×